Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update

- Interim Jan-2025 results from three trials of Alpha DaRT^® in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium and R&D Update Day, showing >90% disease control rate, impressive overall survival in sub-group analyses, and positive safety profile -